Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE) (Illuminate-X)

NCT01488708 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01488708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01488708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE) (Illuminate-X)
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2012
Completion date
October 31, 2015
Enrollment
1,518 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune disease, connective tissue disease, systemic lupus erythematosus